Premium
Florbetapir positron emission tomography and cerebrospinal fluid biomarkers
Author(s) -
Hake Ann,
Trzepacz Paula T.,
Wang Shufang,
Yu Peng,
Case Michael,
Hochstetler Helen,
Witte Michael M.,
Degenhardt Elisabeth K.,
Dean Robert A.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.03.002
Subject(s) - positron emission tomography , neuroimaging , cerebrospinal fluid , standardized uptake value , posterior cingulate , logistic regression , alzheimer's disease neuroimaging initiative , dementia , psychology , nuclear medicine , medicine , alzheimer's disease , neuroscience , disease , cognition
Background We evaluated the relationship between florbetapir‐F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers. Methods Alzheimer's Disease Neuroimaging Initiative‐Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression. Results In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ 1–42 ) and tau/Aβ 1–42 ratios. Using logistic regression, Aβ 1–42 , total tau (t‐tau), phosphorylated tau 181P (p‐tau), and FBP PET composite each differentiated HC versus AD. Aβ 1–42 and t‐tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p‐tau added discriminative power to FBP PET when classifying HC versus AD. Conclusion Based on cross‐sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.